Articles

< Previous         Next >  
DBC1 phosphorylation by ATM/ATR inhibits SIRT1 deacetylase in response to DNA damage Free
Laura Zannini1,†, Giacomo Buscemi1,†, Ja-Eun Kim2, Enrico Fontanella1, and Domenico Delia1,*
1Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, I-20133 Milan, Italy
2Department of Pharmacology, School of Medicine, Kyung Hee University, 1 Hoegi-Dong, Dongdaemun-gu, Seoul 130-701, Republic of Korea *Correspondence to:Domenico Delia, E-mail: domenico.delia@istitutotumori.mi.it
J Mol Cell Biol, Volume 4, Issue 5, October 2012, 294-303,  https://doi.org/10.1093/jmcb/mjs035
Keyword: DBC1, phosphorylation, SIRT1 deacetylase, DNA damage
Human DBC1 (deleted in breast cancer-1; KIAA1967) is a nuclear protein that, in response to DNA damage, competitively inhibits the NAD+-dependent deacetylase SIRT1, a regulator of p53 apoptotic functions in response to genotoxic stress. DBC1 depletion in human cells increases SIRT1 activity, resulting in the deacetylation of p53 and protection from apoptosis. However, the mechanisms regulating this process have not yet been determined. Here, we report that, in human cell lines, DNA damage triggered the phosphorylation of DBC1 on Thr454 by ATM (ataxia telangiectasia-mutated) and ATR (ataxia telangiectasia and Rad3-related) kinases. Phosphorylated DBC1 bound to and inhibited SIRT1, resulting in the dissociation of the SIRT1–p53 complex and stimulating p53 acetylation and p53-dependent cell death. Indeed, DBC1-mediated genotoxicity, which was shown in knockdown experiments to be dependent on SIRT1 and p53 expression, was defective in cells expressing the phospho-mutant DBC1T454A. This study describes the first post-translational modification of DBC1 and provides new mechanistic insight linking ATM/ATR to the DBC1–SIRT1–p53 apoptotic axis triggered by DNA damage.